Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF. Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg. 2006;243:189–95.

Article  PubMed  PubMed Central  Google Scholar 

Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.

Article  CAS  PubMed  Google Scholar 

Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery. 1996;119:437–44. https://doi.org/10.1016/S0039-6060(96)80145-0.

Article  CAS  PubMed  Google Scholar 

Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology. 2000;58:96–107. https://doi.org/10.1159/000012086.

Article  CAS  PubMed  Google Scholar 

Available from https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf . Accessed 5 May 2024.

Dindo D. The Clavien–Dindo classification of surgical complications. In: Treatment of postoperative complications after digestive surgery. London: Springer; 2014. pp. 13–7. https://doi.org/10.1007/978-1-4471-4354-3_3

Rosenbaum SJ, Stergar H, Antoch G, Veit P, Bockisch A, Kühl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging. 2006;31:25–35.

Article  CAS  PubMed  Google Scholar 

Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2:3. https://doi.org/10.1186/1477-7800-2-3.

Article  PubMed  PubMed Central  Google Scholar 

Van der Speeten K, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2:63–72. https://doi.org/10.1515/pp-2017-0003.

Article  PubMed  PubMed Central  Google Scholar 

Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370-7.https://doi.org/10.1245/s10434-010-1039-7.

Article  Google Scholar 

Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110:275–84. https://doi.org/10.1002/jso.23633.

Article  PubMed  PubMed Central  Google Scholar 

Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028–40. https://doi.org/10.1200/JCO.18.01688.

Article  CAS  PubMed  Google Scholar 

Rau B, Lang H, Königsrainer A. 1376O The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol. 2021;1:S1040. https://doi.org/10.1016/j.annonc.2021.08.1485.

Article  Google Scholar 

Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:911–9. https://doi.org/10.1016/j.ejso.2015.03.231.

Article  CAS  PubMed  Google Scholar 

Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81. https://doi.org/10.1245/s10434-011-1631-5.

Article  PubMed  PubMed Central  Google Scholar 

Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971–9. https://doi.org/10.1245/s10434-015-5081-3.

Article  CAS  PubMed  Google Scholar 

Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85.

Article  PubMed  PubMed Central  Google Scholar 

Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21:1147–52. https://doi.org/10.1245/s10434-013-3443-2.

Article  PubMed  Google Scholar 

Manzanedo I, Pereira F, Rihuete Caro C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;15:2615–21. https://doi.org/10.1245/s10434-019-07450-4.

Article  Google Scholar 

Rau B, Brandl A, Piso P, et al. Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2020;23:11–22. https://doi.org/10.1007/s10120-019-00978-0.

Article  PubMed  Google Scholar